NCT01043874 - Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2013

Study Completion Date

January 31, 2014

Conditions

Philadelphia Chromosome PositiveChronic Myelogenous Leukemia in Chronic Phase

Interventions

DRUG

Nilotinib

400 mg BID

Trial Locations (20)

453-8511

Novartis Investigative Site, Nagoya

464-8681

Novartis Investigative Site, Nagoya

466-8560

Novartis Investigative Site, Nagoya

030-8553

Novartis Investigative Site, Aomori

812-8582

Novartis Investigative Site, Fukuoka

807-8556

Novartis Investigative Site, Kitakyushu

501-1194

Novartis Investigative Site, Gifu

734-8551

Novartis Investigative Site, Hiroshima

860-8556

Novartis Investigative Site, Kumamoto

602-8566

Novartis Investigative Site, Kyoto

983-8520

Novartis Investigative Site, Sendai

852-8501

Novartis Investigative Site, Nagasaki

700-8558

Novartis Investigative Site, Okayama

545-8586

Novartis Investigative Site, Osaka

589-8511

Novartis Investigative Site, Sayama

565-0871

Novartis Investigative Site, Suita

849-8501

Novartis Investigative Site, Saga

113-8519

Novartis Investigative Site, Bunkyo-ku

113-8655

Novartis Investigative Site, Bunkyo-ku

160-0023

Novartis Investigative Site, Shinjuku-ku